| Molecule | Cat. No. | Product Name | 種 | Host | Structure | Purity | Activity | Size&Price |
|---|---|---|---|---|---|---|---|---|
| HLA-A*2601 & B2M | Biotinylated Human HLA-A*26:01&B2M Monomer Protein (Peptide free, MALS verified) | Human | HEK293 | MALSSDS-PAGE | $125.00 25ug |
| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| Latozinemab | AL-001; GSK-4527223 | Phase 3 Clinical | Alector Inc, Glaxosmithkline Plc | Bipolar Disorder; Amyotrophic Lateral Sclerosis; Frontotemporal Dementia; Neurodegenerative Diseases | 詳細 |
| VES-001 | VES-001; VES001 | Phase 1 Clinical | Vesper Bio APS | Dementia; Frontotemporal Dementia | 詳細 |